Associations - patritumab deruxtecan (U3-1402)

EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	U3-1402 Sensitive: B - Late Trials U3-1402 Sensitive : B	U3-1402 Sensitive: B - Late Trials U3-1402 Sensitive : B
ERBB3 expression	Colorectal Cancer	ERBB3 expression	Colorectal Cancer	U3-1402 Sensitive: C2 – Inclusion Criteria U3-1402 Sensitive : C2	U3-1402 Sensitive: C2 – Inclusion Criteria U3-1402 Sensitive : C2
ERBB3 expression	Breast Cancer	ERBB3 expression	Breast Cancer	U3-1402 Sensitive: C2 – Inclusion Criteria U3-1402 Sensitive : C2	U3-1402 Sensitive: C2 – Inclusion Criteria U3-1402 Sensitive : C2
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	U3-1402 Sensitive: C2 – Inclusion Criteria U3-1402 Sensitive : C2	U3-1402 Sensitive: C2 – Inclusion Criteria U3-1402 Sensitive : C2
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	U3-1402 Sensitive: C2 – Inclusion Criteria U3-1402 Sensitive : C2	U3-1402 Sensitive: C2 – Inclusion Criteria U3-1402 Sensitive : C2
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	U3-1402 Sensitive: C2 – Inclusion Criteria U3-1402 Sensitive : C2	U3-1402 Sensitive: C2 – Inclusion Criteria U3-1402 Sensitive : C2
ALK fusion	Non Small Cell Lung Cancer	ALK fusion	Non Small Cell Lung Cancer	U3-1402 Sensitive: C2 – Inclusion Criteria U3-1402 Sensitive : C2	U3-1402 Sensitive: C2 – Inclusion Criteria U3-1402 Sensitive : C2
ROS1 fusion	Non Small Cell Lung Cancer	ROS1 fusion	Non Small Cell Lung Cancer	U3-1402 Sensitive: C2 – Inclusion Criteria U3-1402 Sensitive : C2	U3-1402 Sensitive: C2 – Inclusion Criteria U3-1402 Sensitive : C2
HER-2 negative	Triple Negative Breast Cancer	HER-2 negative	Triple Negative Breast Cancer	U3-1402 Sensitive: C2 – Inclusion Criteria U3-1402 Sensitive : C2	U3-1402 Sensitive: C2 – Inclusion Criteria U3-1402 Sensitive : C2
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	U3-1402 Sensitive: C2 – Inclusion Criteria U3-1402 Sensitive : C2	U3-1402 Sensitive: C2 – Inclusion Criteria U3-1402 Sensitive : C2
EGFR C797S	Non Small Cell Lung Cancer	EGFR C797S	Non Small Cell Lung Cancer	U3-1402 Sensitive: C3 – Early Trials U3-1402 Sensitive : C3	U3-1402 Sensitive: C3 – Early Trials U3-1402 Sensitive : C3
MET amplification	Non Small Cell Lung Cancer	MET amplification	Non Small Cell Lung Cancer	U3-1402 Sensitive: C3 – Early Trials U3-1402 Sensitive : C3	U3-1402 Sensitive: C3 – Early Trials U3-1402 Sensitive : C3
HER-2 mutation	Non Small Cell Lung Cancer	HER-2 mutation	Non Small Cell Lung Cancer	U3-1402 Sensitive: C3 – Early Trials U3-1402 Sensitive : C3	U3-1402 Sensitive: C3 – Early Trials U3-1402 Sensitive : C3
BRAF fusion	Non Small Cell Lung Cancer	BRAF fusion	Non Small Cell Lung Cancer	U3-1402 Sensitive: C3 – Early Trials U3-1402 Sensitive : C3	U3-1402 Sensitive: C3 – Early Trials U3-1402 Sensitive : C3
PIK3CA mutation	Non Small Cell Lung Cancer	PIK3CA mutation	Non Small Cell Lung Cancer	U3-1402 Sensitive: C3 – Early Trials U3-1402 Sensitive : C3	U3-1402 Sensitive: C3 – Early Trials U3-1402 Sensitive : C3
HR positive + ERBB3 underexpression	HER2 Negative Breast Cancer	HR positive + ERBB3 underexpression	HER2 Negative Breast Cancer	U3-1402 Sensitive: C3 – Early Trials U3-1402 Sensitive : C3	U3-1402 Sensitive: C3 – Early Trials U3-1402 Sensitive : C3
HR positive + ERBB3 overexpression	HER2 Negative Breast Cancer	HR positive + ERBB3 overexpression	HER2 Negative Breast Cancer	U3-1402 Sensitive: C3 – Early Trials U3-1402 Sensitive : C3	U3-1402 Sensitive: C3 – Early Trials U3-1402 Sensitive : C3
ERBB3 overexpression	Breast Cancer	ERBB3 overexpression	Breast Cancer	U3-1402 Sensitive: C3 – Early Trials U3-1402 Sensitive : C3	U3-1402 Sensitive: C3 – Early Trials U3-1402 Sensitive : C3
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	U3-1402 Sensitive: C3 – Early Trials U3-1402 Sensitive : C3	U3-1402 Sensitive: C3 – Early Trials U3-1402 Sensitive : C3
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	U3-1402 Sensitive: C3 – Early Trials U3-1402 Sensitive : C3	U3-1402 Sensitive: C3 – Early Trials U3-1402 Sensitive : C3
HR positive + HER-2 underexpression	Breast Cancer	HR positive + HER-2 underexpression	Breast Cancer	U3-1402 Sensitive: C3 – Early Trials U3-1402 Sensitive : C3	U3-1402 Sensitive: C3 – Early Trials U3-1402 Sensitive : C3
NRAS mutation	Non Small Cell Lung Cancer	NRAS mutation	Non Small Cell Lung Cancer	U3-1402 Sensitive: C4 – Case Studies U3-1402 Sensitive : C4	U3-1402 Sensitive: C4 – Case Studies U3-1402 Sensitive : C4
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	osimertinib + U3-1402 Sensitive: D – Preclinical osimertinib + U3-1402 Sensitive : D	osimertinib + U3-1402 Sensitive: D – Preclinical osimertinib + U3-1402 Sensitive : D
ERBB3 overexpression	Colorectal Cancer	ERBB3 overexpression	Colorectal Cancer	U3-1402 Sensitive: D – Preclinical U3-1402 Sensitive : D	U3-1402 Sensitive: D – Preclinical U3-1402 Sensitive : D
ERBB3 expression	Melanoma	ERBB3 expression	Melanoma	U3-1402 Sensitive: D – Preclinical U3-1402 Sensitive : D	U3-1402 Sensitive: D – Preclinical U3-1402 Sensitive : D
ERBB3 expression	Estrogen Receptor Positive Breast Cancer	ERBB3 expression	Estrogen Receptor Positive Breast Cancer	U3-1402 Sensitive: D – Preclinical U3-1402 Sensitive : D	U3-1402 Sensitive: D – Preclinical U3-1402 Sensitive : D
ERBB3 mutation	Breast Cancer	ERBB3 mutation	Breast Cancer	U3-1402 Sensitive: D – Preclinical U3-1402 Sensitive : D	U3-1402 Sensitive: D – Preclinical U3-1402 Sensitive : D
ERBB3 expression	Estrogen Receptor Positive Breast Cancer	ERBB3 expression	Estrogen Receptor Positive Breast Cancer	U3-1402 + BAY 1895344 Sensitive: D – Preclinical U3-1402 + BAY 1895344 Sensitive : D	U3-1402 + BAY 1895344 Sensitive: D – Preclinical U3-1402 + BAY 1895344 Sensitive : D

patritumab deruxtecan (U3-1402)

Associations
(28)

Associations
(28)

patritumab deruxtecan (U3-1402)

Associations(28)

Associations(28)

Associations
(28)

Associations
(28)